BioSpace News Archive

COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022.

Clene Inc. today reported that it has received a positive opinion for its submission requesting Orphan Drug Designation for CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS).

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose “Pepe” Carmona to its Board of Directors.

Tectonic Therapeutic , Inc. today announced the promotion of Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics Manufacturing.

Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. (“Offeror”), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the “Offer”) to acquire (the “Acquisition”) all of the outstanding shares of common stock, par value $0.0001 per share (“Common Stock”), of Turning Point Therapeutics, Inc.

Huma.AI, a leading healthcare AI company that provides transformative, human-centric machine learning technology solutions to help drive life science innovation, today announced the appointment of Karen Drexler to its board of directors and Jean-Olivier ‘J-O’ Racine to its strategic advisory board.

Fact.MR, a market research and competitive intelligence provider: Sales in the global medical superabsorbent polymers market are expected to surpass US$ 5.66 Bn by 2032, as per a detailed study published by Fact.MR.

Surge in the adoption of advanced technologies such as artificial intelligence across the healthcare sector and growing support by several government authorities for digitalization are some of the prime factors boosting the expansion of the global digital transformation in healthcare market during the forecast period of 2021 to 2031.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The clinical risk grouping solutions market is anticipated to observe steady growth during the forecast period of 2021-2031.

Brii Biosciences Limited announced that TSB Therapeutics Co., Ltd., a joint venture majority-owned by the Company, is partnering with China Resources Pharmaceutical Commercial Group Co., Ltd. to advance stockpiling, channel distribution and hospital access for the Company’s long-acting neutralizing monoclonal antibody therapy, the amubarvimab/romlusevimab combination.